Atlas Trials

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

Clinical trial NCT05645380 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05645380
Sponsor
University of Kansas Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast CancerBreast Cancer
Start date
2022-12-05
Primary completion
2026-12-01
Enrollment
139

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.